Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Voortman, MM; Pekar, T; Bachmayer, D; Archelos, JJ; Stojakovic, T; Scharnagl, H; Ropele, S; Pichler, A; Enzinger, C; Fuchs, S; Fazekas, F; Seifert-Held, T; Khalil, M.
Serum netrin-1 in relation to gadolinium-enhanced magnetic resonance imaging in early multiple sclerosis.
Mult Scler J Exp Transl Clin. 2017; 3(3):2055217317727294-2055217317727294
Doi: 10.1177/2055217317727294
[OPEN ACCESS]
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Khalil Michael
- Voortman Margarete Maria
- Co-authors Med Uni Graz
- Archelos-Garcia Juan-Jose
- Enzinger Christian
- Fazekas Franz
- Fuchs Siegrid
- Pekar Thomas
- Pichler Alexander
- Ropele Stefan
- Scharnagl Hubert
- Seifert-Held Thomas
- Stojakovic Tatjana
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Netrin-1, a secreted laminin-related protein, is known to regulate not only axonal guidance and neuronal cell migration, but also blood-brain barrier integrity and inflammation. Two preliminary studies reported altered serum netrin-1 levels in multiple sclerosis; however, associations with longitudinal clinical and magnetic resonance imaging activity have not been investigated. We aimed to assess serum netrin-1 in multiple sclerosis and controls with respect to disease activity and its temporal dynamics. Serum netrin-1 was assessed by enzyme-linked immunosorbent assay in 79 patients with clinically isolated syndrome or multiple sclerosis, and 30 non-inflammatory neurological disease controls. In patients, serum samples were collected immediately prior to gadolinium-enhanced 3 T magnetic resonance imaging at two time points (initial contrast-enhancing gadolinium+ n = 47, non-enhancing gadolinium- n = 32; reference gadolinium- n = 70; median time-lag 1.4, interquartile range 1.0-2.3 years). Serum netrin-1 levels were similar in clinically isolated syndrome, multiple sclerosis and controls, and gadolinium+ and gadolinium- patients. Among gadolinium+ patients, serum netrin-1 was decreased in clinically active (n = 8) vs non-active patients (n = 39; p = 0.041). Serum netrin-1 showed no temporal dynamics in multiple sclerosis and was unrelated to clinical data. Serum netrin-1 levels show no multiple sclerosis specific changes and are not sensitive for detection of subclinical disease activity. Netrin-1 changes during relapses may deserve further examination.